# EDGAR Filing Document

**Accession Number:** 0001827635
**File Stem:** 0000899140-26-000173
**Filing Date:** 2026-2
**Character Count:** 36120
**Document Hash:** 4860201b24bd778e50f79ebcc29b523f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899140-26-000173.hdr.sgml**: 20260211

**ACCESSION NUMBER**: 0000899140-26-000173

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20260211

**DATE AS OF CHANGE**: 20260211

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Veradermics, Inc
- **CENTRAL INDEX KEY:** 0001827635
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 843304423
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95484
- **FILM NUMBER:** 26622100

**BUSINESS ADDRESS:**
- **STREET 1:** 470 JAMES STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06513
- **BUSINESS PHONE:** 228.372.3376

**MAIL ADDRESS:**
- **STREET 1:** 470 JAMES STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06513

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VeraDermics, Inc
- **DATE OF NAME CHANGE:** 20201008
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SUVRETTA CAPITAL MANAGEMENT, LLC
- **CENTRAL INDEX KEY:** 0001569064

**ORGANIZATION NAME:**
- **EIN:** 453704500
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 540 MADISON AVENUE
- **STREET 2:** 7TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 2127025204

**MAIL ADDRESS:**
- **STREET 1:** 540 MADISON AVENUE
- **STREET 2:** 7TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

## Ex-1

Exhibit 1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k), as promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock, par value $0.00001 per share of Veradermics, Incorporated and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of February 11, 2026.

Dated: February 11, 2026

---

| | | |
|:---|:---|:---|
| AVERILL MASTER FUND, LTD. | AVERILL MASTER FUND, LTD. | AVERILL MASTER FUND, LTD. |
| By: | <u>/s/ Andrew Nathanson&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>  | <u>/s/ Andrew Nathanson&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>  |
|  | Name: | Andrew Nathanson |
|  | Title: | Authorized Signatory |
| AVERILL MADISON MASTER FUND, LTD. | AVERILL MADISON MASTER FUND, LTD. | AVERILL MADISON MASTER FUND, LTD. |
| By: | <u>/s/ Andrew Nathanson&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>  | <u>/s/ Andrew Nathanson&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>  |
|  | Name: | Andrew Nathanson |
|  | Title: | Authorized Signatory |
| SUVRETTA CAPITAL MANAGEMENT, LLC | SUVRETTA CAPITAL MANAGEMENT, LLC | SUVRETTA CAPITAL MANAGEMENT, LLC |
| By: | <u>/s/ Andrew Nathanson&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>  | <u>/s/ Andrew Nathanson&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>  |
|  | Name: | Andrew Nathanson |
|  | Title: | General Counsel and Chief Compliance Officer |
| <u>/s/ Aaron Cowen&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>  | <u>/s/ Aaron Cowen&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>  | <u>/s/ Aaron Cowen&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>  |
| Aaron Cowen | Aaron Cowen | Aaron Cowen |

---

## Ex-2

#### Schedule I

Set forth below is the name, business address, and present principal occupation of each of the executive officers and directors of each of the Funds and Suvretta Capital. Sherri Fleming is a citizen of Canada. Each other such person is a citizen of the United States.<br>

<u>Averill Master Fund, Ltd.</u>

---

| | | |
|:---|:---|:---|
| Name | Present Business Address | Present Principal Occupation |
| Directors: | Directors: | Directors: |
| Sherri Fleming | Maples Fiduciary Services (Cayman) Limited<br> c/o PO Box 309<br> Ugland House<br> Grand Cayman, KY1-1104<br> Cayman Islands | Vice President of Maples Fiduciary Services (Cayman) Limited |
| William Shaw | Maples Fiduciary Services (Cayman) Limited<br> c/o PO Box 309<br> Ugland House<br> Grand Cayman, KY1-1104<br> Cayman Islands | Senior Vice President of Maples Fiduciary Services (Cayman) Limited |
| Aaron Cowen | c/o Suvretta Capital Management, LLC<br> 540 Madison Avenue, 7th Floor<br> New York, NY 10022 | Managing Member, Suvretta Capital Management, LLC |

---

<u>Averill Madison Master Fund, Ltd.</u>

---

| | | |
|:---|:---|:---|
| Name | Present Business Address | Present Principal Occupation |
| Directors: | Directors: | Directors: |
| Sherri Fleming | Maples Fiduciary Services (Cayman) Limited<br> c/o PO Box 309<br> Ugland House<br> Grand Cayman, KY1-1104<br> Cayman Islands | Vice President of Maples Fiduciary Services (Cayman) Limited |
| William Shaw | Maples Fiduciary Services (Cayman) Limited<br> c/o PO Box 309<br> Ugland House<br> Grand Cayman, KY1-1104<br> Cayman Islands | Senior Vice President of Maples Fiduciary Services (Cayman) Limited |
| Kishan Mehta | c/o Suvretta Capital Management, LLC<br> 540 Madison Avenue, 7th Floor<br> New York, NY 10022 | Portfolio Manager, Suvretta Capital Management, LLC |

---

<u>Suvretta Capital Management, LLC</u>

---

| | | |
|:---|:---|:---|
| Name | Present Business Address | Present Principal Occupation |
| Officers: | Officers: | Officers: |
| Aaron Cowen | c/o Suvretta Capital Management, LLC<br> 540 Madison Avenue, 7th Floor<br> New York, NY 10022 | Managing Member |
| Glenn Shepard | c/o Suvretta Capital Management, LLC<br> 540 Madison Avenue, 7th Floor<br> New York, NY 10022 | Chief Financial Officer |
| Andrew Nathanson | c/o Suvretta Capital Management, LLC<br> 540 Madison Avenue, 7th Floor<br> New York, NY 10022 | General Counsel and Chief Compliance Officer |

---

## Ex-3

Schedule II

#### <br>

#### Transactions in Common Stock
(60-day period ended February 11, 2026)<br>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Reporting Person** | **Date** | **Amount** | **Price Per Share** |  | **Buy/Sell** | **Execution Type** |
| Averill Master Fund, Ltd. | 2/4/2026 | 10004 | $34.25 | (1) | Buy | New York Stock Exchange |
| Averill Master Fund, Ltd. | 2/4/2026 | 10676 | $34.74 | (2) | Buy | New York Stock Exchange |
| Averill Master Fund, Ltd. | 2/4/2026 | 14659 | $36.27 | (3) | Buy | New York Stock Exchange |
| Averill Master Fund, Ltd. | 2/4/2026 | 53344 | $37.11 | (4) | Buy | New York Stock Exchange |
| Averill Master Fund, Ltd. | 2/4/2026 | 25908 | $38.09 | (5) | Buy | New York Stock Exchange |
| Averill Master Fund, Ltd. | 2/4/2026 | 18489 | $38.90 | (6) | Buy | New York Stock Exchange |
| Averill Madison Master Fund, Ltd. | 2/4/2026 | 1720 | $34.25 | (1) | Buy | New York Stock Exchange |
| Averill Madison Master Fund, Ltd. | 2/4/2026 | 1835 | $34.74 | (2) | Buy | New York Stock Exchange |
| Averill Madison Master Fund, Ltd. | 2/4/2026 | 2519 | $36.27 | (3) | Buy | New York Stock Exchange |
| Averill Madison Master Fund, Ltd. | 2/4/2026 | 9168 | $37.11 | (4) | Buy | New York Stock Exchange |
| Averill Madison Master Fund, Ltd. | 2/4/2026 | 4453 | $38.09 | (5) | Buy | New York Stock Exchange |
| Averill Madison Master Fund, Ltd. | 2/4/2026 | 3178 | $38.90 | (6) | Buy | New York Stock Exchange |
| Averill Master Fund, Ltd. | 2/5/2026 | 424421 | N/A |  | Buy | Acquisition upon conversion of Series B Preferred Stock |
| Averill Master Fund, Ltd. | 2/5/2026 | 877497 | N/A |  | Buy | Acquisition upon conversion of Series C Preferred Stock |
| Averill Master Fund, Ltd. | 2/5/2026 | 1813540 | $17.00 |  | Buy | Acquisition in the Initial Offering |
| Averill Madison Master Fund, Ltd. | 2/5/2026 | 59399 | N/A |  | Buy | Acquisition upon conversion of Series C Preferred Stock |
| Averill Madison Master Fund, Ltd. | 2/5/2026 | 311460 | $17.00 |  | Buy | Acquisition in the Initial Offering |
| Averill Madison Master Fund, Ltd. | 2/5/2026 | 3832 | $36.07 | (7) | Buy | New York Stock Exchange |
| Averill Madison Master Fund, Ltd. | 2/5/2026 | 19199 | $36.93 | (8) | Buy | New York Stock Exchange |
| Averill Madison Master Fund, Ltd. | 2/5/2026 | 38771 | $37.63 | (9) | Buy | New York Stock Exchange |
| Averill Madison Master Fund, Ltd. | 2/5/2026 | 17835 | $38.67 | (10) | Buy | New York Stock Exchange |
| Averill Madison Master Fund, Ltd. | 2/5/2026 | 16563 | $39.80 | (11) | Buy | New York Stock Exchange |
| Averill Madison Master Fund, Ltd. | 2/6/2026 | 11183 | $35.97 | (12) | Buy | New York Stock Exchange |
| Averill Madison Master Fund, Ltd. | 2/6/2026 | 19338 | $36.55 | (13) | Buy | New York Stock Exchange |

---

(1) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $33.50 to $34.50.
 The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, the full information regarding the number of shares purchased at each separate
 price within the ranges set forth above.

(2) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $34.53 to $35.42. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or
 the staff at the Securities and Exchange Commission, upon request, the full information regarding the number of shares purchased at each separate price within the ranges set forth above. <br>

(3) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.55 to $36.55. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or
 the staff at the Securities and Exchange Commission, upon request, the full information regarding the number of shares purchased at each separate price within the ranges set forth above. <br>

(4) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $36.56 to $37.56. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or
 the staff at the Securities and Exchange Commission, upon request, the full information regarding the number of shares purchased at each separate price within the ranges set forth above. <br>

(5) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.57 to $38.57. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or
 the staff at the Securities and Exchange Commission, upon request, the full information regarding the number of shares purchased at each separate price within the ranges set forth above. <br>

(6) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.58 to $39.50. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or
 the staff at the Securities and Exchange Commission, upon request, the full information regarding the number of shares purchased at each separate price within the ranges set forth above. <br>

(7) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.14 to $36.14. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or
 the staff at the Securities and Exchange Commission, upon request, the full information regarding the number of shares purchased at each separate price within the ranges set forth above. <br>

(8) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $36.18 to $37.18. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or
 the staff at the Securities and Exchange Commission, upon request, the full information regarding the number of shares purchased at each separate price within the ranges set forth above. <br>

(9) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.19 to $38.18. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or
 the staff at the Securities and Exchange Commission, upon request, the full information regarding the number of shares purchased at each separate price within the ranges set forth above. <br>

(10) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.20 to $39.20. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or
 the staff at the Securities and Exchange Commission, upon request, the full information regarding the number of shares purchased at each separate price within the ranges set forth above. <br>

(11) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.21 to $40.00. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or
 the staff at the Securities and Exchange Commission, upon request, the full information regarding the number of shares purchased at each separate price within the ranges set forth above. <br>

(12) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.26 to $36.26. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or
 the staff at the Securities and Exchange Commission, upon request, the full information regarding the number of shares purchased at each separate price within the ranges set forth above. <br>

(13) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $36.26 to $37.26.
 The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, the full information regarding the number of shares purchased at each separate
 price within the ranges set forth above.

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Veradermics, Inc**

*(Name of Issuer)*

**Common Stock, par value $0.00001**

*(Title of Class of Securities)*

**922967104**

*(CUSIP Number)*

**Andrew Nathanson**<br>Suvretta Capital Management, LLC<br>540 Madison Avenue, 7th Floor<br>New York NY 10022<br>(212) 702-5205

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**02/05/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **922967104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**SUVRETTA CAPITAL MANAGEMENT, LLC** | Name of reporting person<br>**SUVRETTA CAPITAL MANAGEMENT, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**4168991.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**4168991.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4168991.00** | Aggregate amount beneficially owned by each reporting person<br>**4168991.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**11.9%** | Percent of class represented by amount in Row (11)<br>**11.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

**Comment for Reporting Person:** Note in relation to Item 13: Based on 35,077,084 shares of Common Stock (as defined below) outstanding, as indicated by the Issuer (as defined below) in the Final Prospectus (as defined below) on February 4, 2026.

| **CUSIP No.** | **922967104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Averill Master Fund, Ltd.** | Name of reporting person<br>**Averill Master Fund, Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3648538.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3648538.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3648538.00** | Aggregate amount beneficially owned by each reporting person<br>**3648538.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**10.4%** | Percent of class represented by amount in Row (11)<br>**10.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** Note in relation to Item 13: Based on 35,077,084 shares of Common Stock (as defined below) outstanding, as indicated by the Issuer (as defined below) in the Final Prospectus (as defined below) on February 4, 2026.

| **CUSIP No.** | **922967104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Averill Madison Master Fund, Ltd.** | Name of reporting person<br>**Averill Madison Master Fund, Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**520453.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**520453.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**520453.00** | Aggregate amount beneficially owned by each reporting person<br>**520453.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.5%** | Percent of class represented by amount in Row (11)<br>**1.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** Note in relation to Item 13: Based on 35,077,084 shares of Common Stock (as defined below) outstanding, as indicated by the Issuer (as defined below) in the Final Prospectus (as defined below) on February 4, 2026.

| **CUSIP No.** | **922967104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Aaron Cowen** | Name of reporting person<br>**Aaron Cowen** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**4168991.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**4168991.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4168991.00** | Aggregate amount beneficially owned by each reporting person<br>**4168991.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**11.9%** | Percent of class represented by amount in Row (11)<br>**11.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Note in relation to Item 13: Based on 35,077,084 shares of Common Stock (as defined below) outstanding, as indicated by the Issuer (as defined below) in the Final Prospectus (as defined below) on February 4, 2026.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.00001

**(b) Name of Issuer:**
Veradermics, Inc

**(c) Address of Issuer's Principal Executive Offices:**
470 James Street, New Haven, CT, 06513

This statement on Schedule 13D (this "Schedule 13D") relates to shares of common stock, par value $0.00001 per share ("Common Stock"), of Veradermics, Incorporated, a Delaware corporation (the "Issuer"). The principal executive office of the Issuer is 470 James Street, New Haven, Connecticut 06513.

**Item 4. Purpose of Transaction**

The disclosure in Item 3 above is incorporated herein by reference.

	The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of shares of Common Stock or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, the attitudes and actions of the board of directors of the Issuer (the "Board") and management of the Issuer, and the availability and nature of opportunities to dispose of securities of the Issuer. The Reporting Persons may discuss items of mutual interest with the Issuer"s management, other members of the Board and other investors, which could include items in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

	Depending upon their assessments of the above factors, the Reporting Persons or their affiliates may change their present intentions as stated above and they may assess whether to make suggestions to the management of the Issuer regarding financing, and whether to acquire additional securities of the Issuer (by means of open market purchases, privately negotiated purchases, or otherwise) or to dispose of some or all of the securities of the Issuer under their control.

	In December 2025, David Friedman, M.D., was appointed to the Board.  Dr. Friedman serves as a Managing Director and Senior Analyst at Suvretta Capital.  Dr. Friedman, in his capacity as a director of the Issuer, may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. 
 
	Except as otherwise disclosed herein, at the present time, the Reporting Persons do not have any plans or proposals with respect to any extraordinary corporate transaction involving the Issuer including, without limitation, those matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information contained on the cover pages to this Schedule 13D is incorporated by reference into this Item 5. Mr. Cowen is the control person and managing member of Suvretta Capital and may be deemed to control the other Reporting Persons. Mr. Cowen disclaims beneficial ownership of all shares of Common Stock held by the Funds, other than, to the extent of any pecuniary interest therein. Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that any Reporting Person or any of its affiliates is the beneficial owner of any shares of Common Stock for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

**(b)**
The information contained on the cover pages to this Schedule 13D is incorporated by reference into this Item 5.

**(c)**
The information disclosed in Item 3 and on Schedule II is incorporated by reference into this Item 5.  Except as disclosed in Item 3 above and in this Item 5(c), the Reporting Persons and, to their knowledge, the Scheduled Persons have not effected any transactions in Common Stock during the past sixty days.  Schedule II sets forth the transactions in Common Stock that were effected by the Reporting Persons during the past sixty days.  The transactions in Common Stock described on Schedule II were effected on securities exchanges unless otherwise indicated therein.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Investors' Rights Agreement

	In connection with the issuance of the Series C Preferred Stock, on October 14, 2025, the Issuer entered into a Third Amended and Restated Investors' Rights Agreement (the "Investors' Rights Agreement") with certain holders of the Issuer's capital stock (the "Investors"), including the purchasers of the Issuer's Series C Preferred Stock and other specified stockholders named therein, including the Funds, pursuant to which the Issuer granted certain registration rights in respect of (i) shares of the Issuer's Common Stock issued or issuable upon conversion of the Issuer's preferred stock, (ii) shares of the Issuer's Common Stock, or shares of the Issuer's Common Stock  issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Issuer, acquired by the Investors following the date of the Investors' Rights Agreement and prior to the consummation of the Initial Offering, and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i), (ii) and (iii) (the "Registrable Securities"). Under the Investors' Rights Agreement, at any time beginning 180 days after January 30, 2026, the Issuer has agreed to file a registration statement on Form S-1 covering the resale of a majority of the Registrable Securities then outstanding by no later than the 60 days following a request by the holders of at least 35% of the Registrable Securities then outstanding, if the aggregate offering price of the Registrable Securities requested to be registered would exceed $20 million.  Once the Issuer is eligible to use a registration statement on Form S-3, the Issuer has agreed to file a registration statement on Form S-3 covering the resale of Registrable Securities then outstanding and held by the holders of not less than 20% of the Registrable Securities then outstanding by no later than 45 days following a request by such holders, if the aggregate offering price of the Registrable Securities requested to be registered would exceed $1 million.  In the event that the Issuer proposes to register any of its securities under the Securities Act of 1933, as amended, either for its own account or for the account of other security holders, the Issuer has agreed to include the Registrable Securities held by the stockholders party to the Investors' Rights Agreement in such registration, subject to certain marketing and other limitations.  Whenever required under the Investors' Rights Agreement to effect the registration of any Registrable Securities, the Issuer must use its commercially reasonable efforts to cause such registration statement to become effective as expeditiously as reasonably possible.

Lock-Up Agreements

	On November 25, 2025, each of Averill Master Fund and Averill Madison Master Fund entered into a letter agreement with Jefferies LLC, Leerink Partners LLC, Citigroup Global Markets Inc., and Cantor Fitzgerald & Co., as representatives of the underwriters (together, the "Lock-Up Agreements").  Pursuant to the Lock-Up Agreements, each of Averill Master Fund and Averill Madison Master Fund agreed to certain restrictions on transfer of shares of Common Stock or securities convertible into, exchangeable for, or exercisable for Common Stock, beginning on November 25, 2025 and ending on the date that is 180 days after February 3, 2026.  The restrictions on transfer set forth in the Lock-Up Agreements are subject to customary exceptions. 

	The foregoing descriptions of the material terms of the Investors' Rights Agreement and the Lock-Up Agreements are each qualified in their entirety by reference to those documents, each of which is referenced in Exhibits 2 and 3 hereto, respectively, and is incorporated by reference herein.

	The information disclosed in Items 3, 4 and 5 is incorporated by reference into this Item 6.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** SUVRETTA CAPITAL MANAGEMENT, LLC

**Signature:** /s/ Andrew Nathanson

**Name/Title:** Andrew Nathanson, General Counsel and Chief Compliance Officer

**Date:** 02/11/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Averill Master Fund, Ltd.

**Signature:** /s/ Andrew Nathanson

**Name/Title:** Andrew Nathanson, Authorized Signatory

**Date:** 02/11/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Averill Madison Master Fund, Ltd.

**Signature:** /s/ Andrew Nathanson

**Name/Title:** Andrew Nathanson, Authorized Signatory

**Date:** 02/11/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Aaron Cowen

**Signature:** /s/  Aaron Cowen

**Name/Title:** Aaron Cowen

**Date:** 02/11/2026